Epstein, Judith E <br/><br/>
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.  [electronic resource] 

 -  Vaccine  Apr 2004 
 - 1592-603 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0264-410X 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2004.01.031  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Animals<br/>Antibodies, Protozoan--analysis<br/>B-Lymphocytes--immunology<br/>Female<br/>Hepatitis B Antibodies--biosynthesis<br/>Hepatitis B Surface Antigens--immunology<br/>Humans<br/>Immunization Schedule<br/>Malaria Vaccines--adverse effects<br/>Male<br/>Plasmodium falciparum--immunology<br/>Spores, Protozoan--immunology<br/>T-Lymphocytes--immunology<br/>Vaccines, DNA--adverse effects<br/>Vaccines, Synthetic--adverse effects